ONO PHARMACEUTICAL CO., LTD. (4528) Stock Price

Ono Pharmaceutical Co., Ltd. operates a business focused on the pharmaceutical sector. As of March 31, 2025, the company consists of itself and 26 subsidiaries. It primarily manufactures and sells prescription and over-the-counter pharmaceuticals, with particular emphasis on research and development of prescription drugs. This area is positioned as the company's core business.

The company's affiliates include Deciphera Pharmaceuticals, Inc. and its 11 subsidiaries, which handle clinical development, manufacturing, and sales of pharmaceuticals. Additionally, Ono Pharmaceutical Korea and Taiwan Ono Pharmaceutical Co., Ltd. provide sales and sales support functions. Manufacturing and sales operations are managed by entities such as Ono Pharma Healthcare, Toyo Seiyaku Kasei Co., Ltd., and B-Brand Medico-Dental.

Furthermore, Ono Pharma USA and Ono Pharma UK Limited conduct clinical development and in-licensing/out-licensing activities for pharmaceuticals. Other affiliates include Ono Venture Investment and Ono Digital Health Investment LLC, which support business operations through investment activities.

Since Ono Pharmaceutical's business operates as a single pharmaceutical segment, detailed segment information disclosure is omitted. This approach allows the company to enhance its expertise in the pharmaceutical field and achieve efficient business operations.

Ono Pharmaceutical is committed to its corporate mission of "advancing human efforts against disease and suffering" by pursuing the creation of innovative new drugs. The company aims to establish itself as a global specialty pharmaceutical company that addresses unmet medical needs and contributes to the realization of a sustainable society.

The company's growth strategy consists of four pillars. First, under "maximizing product value," the company advances drug development and marketing from a patient-centric perspective, with particular emphasis on strengthening clinical trials in the oncology field. Second, under "pipeline strengthening," the company creates new drugs in priority research areas such as cancer and immune diseases, building a highly differentiated pipeline.

Under "expanding and accelerating global business," the company strengthens its sales foundation in the US and Europe through the acquisition of Descipher Biopharmaceuticals and accelerates global expansion. Additionally, under "expanding business domains," the company pursues new value delivery in the healthcare field and is developing new services utilizing digital technology.

To support these growth strategies, Ono Pharmaceutical is focusing on expanding intangible assets including human capital, corporate brand, and digital and IT infrastructure. In particular, the company is advancing digital transformation and building secure IT infrastructure that responds to globalization and change.